keyword
MENU ▼
Read by QxMD icon Read
search

modafinil in obesity

keyword
https://www.readbyqxmd.com/read/29504180/decreased-body-mass-index-during-treatment-with-sodium-oxybate-in-narcolepsy-type-1
#1
Mink S Schinkelshoek, Isabelle M Smolders, Claire E Donjacour, Wisse P van der Meijden, Erik W van Zwet, Rolf Fronczek, Gert Jan Lammers
Narcolepsy type 1 is characterised by an increase in body weight after disease onset, frequently leading to obesity. It was suggested that this weight gain may be counteracted by treatment with sodium oxybate. We here provide longitudinal body mass index data of patients with narcolepsy type 1 after starting treatment with sodium oxybate, compared with patients in whom treatment with modafinil was initiated. Eighty-one individuals with narcolepsy type 1 fulfilled the entry criteria for this retrospective study: 59 had newly started treatment with sodium oxybate and 22 had newly started modafinil...
March 4, 2018: Journal of Sleep Research
https://www.readbyqxmd.com/read/27538329/-management-of-central-hypersomnias
#2
Yves Dauvilliers, Régis Lopez
Central hypersomnias include narcolepsy type 1, type 2 and idiopathic hypersomnia with daytime sleepiness excessive in the foreground of the clinical symptoms. Despite major advances in our understanding of the mechanisms of the narcolepsy type 1 with a low level of hypocretin-1 in cerebrospinal fluid, its current management is only symptomatic. The current management is also only symptomatic for type 2 narcolepsy and idiopathic hypersomnia with an unknown pathophysiology. Treatment options may vary from a single drug targeting several symptoms or several drugs treating a specific symptom...
June 2016: La Revue du Praticien
https://www.readbyqxmd.com/read/27496573/a-systematic-review-and-meta-analysis-of-randomised-controlled-trials-of-treatments-for-clozapine-induced-obesity-and-metabolic-syndrome
#3
REVIEW
Jorge Zimbron, Golam M Khandaker, Chiara Toschi, Peter B Jones, Emilio Fernandez-Egea
Metabolic complications are commonly found in people treated with clozapine. Reviews on the management of this problem have generally drawn conclusions by grouping different types of studies involving patients treated with various different antipsychotics. We carried out a systematic review and meta-analysis of pharmacological and non-pharmacological treatments for clozapine-induced obesity or metabolic syndrome. Two researchers independently searched PubMed and Embase for randomised controlled trials (RCTs) of treatments for clozapine-induced obesity or metabolic syndrome...
September 2016: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
https://www.readbyqxmd.com/read/27155860/treatment-options-for-narcolepsy
#4
REVIEW
Lucie Barateau, Régis Lopez, Yves Dauvilliers
Narcolepsy type 1 and narcolepsy type 2 are central disorders of hypersomnolence. Narcolepsy type 1 is characterized by excessive daytime sleepiness and cataplexy and is associated with hypocretin-1 deficiency. On the other hand, in narcolepsy type 2, cerebrospinal fluid hypocretin-1 levels are normal and cataplexy absent. Despite major advances in our understanding of narcolepsy mechanisms, its current management is only symptomatic. Treatment options may vary from a single drug that targets several symptoms, or multiple medications that each treats a specific symptom...
May 2016: CNS Drugs
https://www.readbyqxmd.com/read/23036267/mazindol-in-narcolepsy-and-idiopathic-and-symptomatic-hypersomnia-refractory-to-stimulants-a-long-term-chart-review
#5
Nandini Nittur, Eric Konofal, Yves Dauvilliers, Patricia Franco, Smaranda Leu-Semenescu, Valérie Cochen De Cock, Clara O Inocente, Sophie Bayard, Sabine Scholtz, Michel Lecendreux, Isabelle Arnulf
OBJECTIVE: Mazindol is a tricyclic, anorectic, non-amphetamine stimulant used in narcolepsy and obesity since 1970. This study aimed to evaluate the long-term benefit/risk ratio in drug-resistant hypersomniacs and cataplexy sufferers. METHODS: By retrospective analysis of the patients' files in the hospitals of Paris-Salpêtrière (n=91), Montpellier (n=40) and Lyon (n=8), the benefit (Epworth Sleepiness Score (ESS), cataplexy frequency, authorization renewal) and tolerance (side-effects, vital signs, electrocardiogram and cardiac echography) of mazindol were assessed...
January 2013: Sleep Medicine
https://www.readbyqxmd.com/read/23011807/treatment-of-dyssomnias-and-parasomnias-in-childhood
#6
Suresh Kotagal
Dyssomnias are sleep disorders associated with complaints of insomnia or hypersomnia. The daytime sleepiness of narcolepsy is treated by a combination of planned daytime naps, regular exercise medications such as modafinil, or salts of methylphenidate, or amphetamine. Cataplexy that accompanies narcolepsy is treated with anticholinergic agents, selective serotonin reuptake inhibitors, or sodium oxybate. Children with neurodevelopmental disabilities such as autism have sleep initiation and maintenance difficulties on a multifactorial basis, with favorable response to melatonin in some patients...
December 2012: Current Treatment Options in Neurology
https://www.readbyqxmd.com/read/22967783/modafinil-and-armodafinil-in-schizophrenia
#7
Chittaranjan Andrade
No abstract text is available yet for this article.
August 2012: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/22303523/the-canadian-network-for-mood-and-anxiety-treatments-canmat-task-force-recommendations-for-the-management-of-patients-with-mood-disorders-and-comorbid-metabolic-disorders
#8
REVIEW
Roger S McIntyre, Mohammad Alsuwaidan, Benjamin I Goldstein, Valerie H Taylor, Ayal Schaffer, Serge Beaulieu, David E Kemp
BACKGROUND: One goal of the Canadian Network for Mood and Anxiety Treatments (CANMAT) is to develop evidence-based and best practice educational programs and recommendations. Our group conducted a comprehensive literature review to provide evidence-based recommendations for treating metabolic comorbidity in individuals with major depressive disorder (MDD) and bipolar disorder (BD). METHODS: We searched PubMed for all English-language articles published January 1966 to November 2010 using BD and MDD cross-referenced with metabolic syndrome, obesity, diabetes mellitus, hypertension, and dyslipidemia...
February 2012: Annals of Clinical Psychiatry: Official Journal of the American Academy of Clinical Psychiatrists
https://www.readbyqxmd.com/read/21521265/somnolence-in-adult-craniopharyngioma-patients-is-a-common-heterogeneous-condition-that-is-potentially-treatable
#9
R K Crowley, C Woods, M Fleming, B Rogers, L A Behan, E P O'Sullivan, T Kane, A Agha, D Smith, R W Costello, C J Thompson
CONTEXT AND OBJECTIVE: Somnolence and obesity are prevalent in craniopharyngioma patients. We hypothesized that somnolence was because of obstructive sleep apnoea in craniopharyngioma patients. DESIGN, PATIENTS AND MEASUREMENTS: We assessed prevalence of somnolence and sleep apnoea in 28 craniopharyngioma and 23 obese controls attending a tertiary referral centre, by means of the Epworth Sleepiness Score (ESS) and polysomnography. All subjects with sleep apnoea were offered continuous positive airway pressure therapy (CPAP) or modafinil...
June 2011: Clinical Endocrinology
https://www.readbyqxmd.com/read/20833530/neuraxial-anaesthesia-for-caesarean-section-in-a-patient-with-narcolepsy-and-cataplexy
#10
S Soltanifar, R Russell
We report the management of a morbidly obese parturient suffering from narcolepsy with cataplexy who presented for caesarean section. Her symptoms were controlled by modafinil and fluoxetine. We administered epidural anaesthesia successfully; surgery was uneventful and recovery was uncomplicated. We discuss some of the issues surrounding parturients with narcolepsy including drug therapy and choice of anaesthetic technique.
October 2010: International Journal of Obstetric Anesthesia
https://www.readbyqxmd.com/read/20190203/assessment-and-management-of-fatigue-in-neuromuscular-disease
#11
REVIEW
Jau-Shin Lou, Michael D Weiss, Gregory T Carter
Fatigue is a common and potentially debilitating symptom of neuromuscular disease (NMD). Studies show that patients with NMD subjectively report increased levels of fatigue. Laboratory testing has demonstrated that patients with NMD show objective physiological signs of increased fatigue, with both central and peripheral components. To date, no treatment has been proven to be truly effective through evidence-based medicine. Thus, the clinician must use a multimodality approach to treating fatigue in patients with NMD...
March 2010: American Journal of Hospice & Palliative Care
https://www.readbyqxmd.com/read/18573275/modafinil-decreases-food-intake-in-humans-subjected-to-simulated-shift-work
#12
Gydmer A Perez, Margaret Haney, Richard W Foltin, Carl L Hart
In a limited number of studies modafinil has been shown to decrease food intake by laboratory animals and humans. The present study represents a secondary data analysis, in which the effects of modafinil on several measures of food intake were determined in humans living in a residential laboratory during simulated shift work. During this 23-day study, a wide selection of food items and beverages were freely available. During this double-blind, within-participant study, volunteers (N = 11) received oral modafinil dose (0, 200, or 400 mg) 1 h after waking for three consecutive days under two shift conditions: day shift and night shift...
October 2008: Pharmacology, Biochemistry, and Behavior
https://www.readbyqxmd.com/read/17162830/new-findings-from-the-bipolar-collaborative-network-clinical-implications-for-therapeutics
#13
REVIEW
Robert M Post, Lori L Altshuler, Mark A Frye, Trisha Suppes, Susan McElroy, Paul E Keck, Gabriele S Leverich, Ralph Kupka, Willem A Nolen, Heinz Grunze
In this article, we highlight recent Bipolar Collaborative Network data. We found that childhood-onset bipolar illness is common, often goes untreated for more than a decade, and carries a poor prognosis. During randomized studies of adjunctive medications in depression: 1) Venlafaxine showed higher switch rates than bupropion or sertraline; 2) Tranylcypromine was as well tolerated as lamotrigine; and 3) Modafinil was more effective than placebo. Finally, in treatment of overweight and obesity, topiramate and sibutramine showed equal efficacy but poor tolerability, and zonisamide data showed that it may be useful for mood and weight loss...
December 2006: Current Psychiatry Reports
https://www.readbyqxmd.com/read/16566781/abusive-prescription-of-psychostimulants-a-study-of-two-cases
#14
Anne-Laure Pélissier-Alicot, Marie-Dominique Piercecchi-Marti, Christophe Bartoli, Erika Kuhlmann, Philippe-Emmanuel Coiffait, Alain Sanvoisin, Dominique Giocanti, Georges Léonetti
Because psychostimulants have serious possible side effects and particular potential for abuse, their therapeutic indications are today exclusively limited to disorders such as obesity, narcolepsy, or attention deficit/hyperactivity disorder. We report two cases of abusive prescription of these drugs. The first concerns a woman who was treated for a 3 kg weight gain with fenproporex for 5 years and presented a withdrawal syndrome when this drug was no longer marketed in France. In the second case, a woman who complained of atypical sleep problems was prescribed modafinil, methylphenidate, clobazam, lormetazepam, meprobamate, and aceprometazine, and was found dead in her home a few weeks later in unexplained circumstances...
March 2006: Journal of Forensic Sciences
https://www.readbyqxmd.com/read/15010183/wake-promoting-agents-with-different-mechanisms-of-action-comparison-of-effects-of-modafinil-and-amphetamine-on-food-intake-and-cardiovascular-activity
#15
RANDOMIZED CONTROLLED TRIAL
Angela P Makris, Craig R Rush, Robert C Frederich, Thomas H Kelly
Despite efforts to achieve a desirable weight, two-thirds of the population has an elevated body weight. Medications are useful in supporting weight loss, but produce adverse effects. This study compared the effects of amphetamine and modafinil on food intake and cardiovascular activity in healthy men and women. Participants (n = 11) completed 11 sessions. In random order, participants received placebo on five separate sessions and single oral doses of modafinil (1.75, 3.5, or 7.0 mg/kg) and amphetamine (0...
April 2004: Appetite
1
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"